Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Hemoadsorpion in Patients With Septic Shock: Efficacy and Safety Evaluation (HAdSS)

Hemoadsorpion in Patients With Septic Shock: Efficacy and Safety Evaluation. A Pilot Multicenter Randomized Controlled Trial

Hemoadsorpion in Patients With Septic Shock: Efficacy and Safety Evaluation. A Pilot Multicenter Randomized Controlled Trial.

The goal of this clinical trial is the estimation of the efficacy and safety of hemoadsorption procedures (LPS (Lipopolysaccharide) and inflammatory mediators adsorption) in participants with septic shock.

The main questions it aims to answer are:

Does hemoadsorption decrease the severity of MODS (multiple organ disfunction syndrome)?

The study will include participants aged 18 to 80 years with a verified diagnosis of septic shock according to SEPSIS 3 criteria, diagnosed within 12 hours, and a SOFA (sequential organ failure assessment) score of 9 or more.

In addition to Standard of Care (SOC), blood purification, including hemoadsorption, will be used. The minimum waiting time after diagnosis of septic shock and initiation of basic therapy before inclusion of the patient in the study therapy is 4 hours.

The choice of procedure will be based on the EAA (Endotoxin Activity Assay) result:

  • for an EAA level of 0.6-0.9, selective lipopolysaccharide (LPS) adsorption with duration from 2 to 10 hours;
  • for an EAA level less than 0.6, inflammatory mediator adsorption with duration from 6 to 12 hours.

The choice of a specific adsorbers within the LPS and inflammatory mediator adsorption group will be based on randomization.

The use of LPS adsorption is planned based on randomization: Toramyxin R-20 or Efferon LPS. The use of inflammatory mediator adsorption is planned based on randomization: Jafron (HA 330) or CytoSorb.

Studieöversikt

Status

Har inte rekryterat ännu

Betingelser

Detaljerad beskrivning

Every participant will receive 2 adsorption procedures. The second procedure will be initiated no later than 24 hours after the initiation of the first procedure.

LPS adsorption will be performed in 38 participants (Efferon LPS in 19 participants and Toramyxin in 19 participants), two procedures per participant.

Inflammatory mediator adsorption will be performed in 38 participants (Jafron HA 330 in 19 participants and CytoSorb in 19 participants), two procedures per participant.

Sample size calculations were performed separately for each treatment cohort. For the endotoxemia cohort (EAA level of 0.6-0.9), this randomized trial is designed to compare Efferron LPS and Toraymyxin with respect to change in SOFA score at 72 hours.

At present, no universally accepted minimal clinically important difference (MCID) has been established for the SOFA score in participants with septic shock. Therefore, the assumed treatment effect was derived from published evidence and expert clinical judgment.

In the EUPHAS trial, polymyxin B hemoperfusion was associated with a mean reduction in SOFA score of approximately 3.4 points at 72 hours, whereas minimal change was observed in the control group. Similarly, the LASSO study demonstrated substantial improvement in organ dysfunction following endotoxin adsorption therapy.

For the inflammatory mediator adsorption cohort (EAA level less than 0.6), this randomized trial is designed to compare CytoSorb and Jafron HA 330 with respect to change in SOFA score at 72 hours.

In the retrospective study Mehta et al., CytoSorb hemoperfusion was associated with a mean reduction in SOFA score of approximately 2.0 points after treatment in survival group. Similarly, the case series Onuk et al. demonstrated substantial improvement in organ dysfunction following inflammatory adsorption therapy with Jafron HA 330 with a mean reduction in SOFA score of approximately 3.5 points at 72 hours.

A between-group difference of 2.5 SOFA points was considered clinically meaningful for both Endotoxin hemoadsorption and inflammatory mediators hemoadsorption because it represents a substantial proportion of the treatment effect observed in previous hemoperfusion studies and corresponds to a clinically relevant difference in the degree of organ dysfunction improvement.

The sample size for both groups (LPS and inflammatory mediator adsorption) was calculated based on the following assumption: the primary endpoint was the change in SOFA score at 72 hours (ΔSOFA); the expected between-group difference - 2.5 points on the SOFA score; standard deviation of ΔSOFA - 2.5 points; equal allocation ratio (1:1); two-sided significance level (α) of 0.05; statistical power of 80%.

Sample size estimation was performed in R using the power.t.test() function. The calculation yielded a required sample size of 16.7 participants per group. Therefore, a minimum of 17 participants per group (34 participants in total) is required to achieve the planned statistical power.

To account for an anticipated 10% dropout rate, the final sample size will be 19 patients per group (38 participants in total for LPS+ 38 participants in total for Inflammatory mediators adsorption. 76 participants in total).

Studietyp

Interventionell

Inskrivning (Beräknad)

76

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

      • Moscow, Ryssland
        • Petrovsky National Research Centre of Surgery
        • Kontakt:
      • Moscow, Ryssland
        • Bakulev Scientific Center of Cardiovascular Surgery
        • Kontakt:
          • Mikhail Yarustovskiy, MD, PHD
          • Telefonnummer: +79104194682
          • E-post: mbyar@yandex.ru
      • Moscow, Ryssland
        • City clinical hospital named after S. S. Yudin, Moscow City Health
        • Kontakt:
      • Moscow, Ryssland
        • City Clinical Hospital No 52, Moscow, Russia
        • Kontakt:
      • Moscow, Ryssland
        • Moscow Multi-disciplinary Clinical Center "Kommunarka"
      • Moscow, Ryssland
        • Sklifosovsky Institute of Emergency Care
        • Kontakt:
      • Rostov-on-Don, Ryssland
        • National Medical Research Centre for Oncology Rostov-on-Don
        • Kontakt:

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Vuxen
  • Äldre vuxen

Tar emot friska volontärer

Nej

Beskrivning

Inclusion Criteria:

  • Septic shock according to SEPSIS-3 criteria
  • Age: 18-80 years
  • SOFA ≥9 points
  • Diagnosis of septic shock established <12 hours ago
  • Invasive hemodynamic monitoring
  • Norepinephrine dose >0.2 mcg/kg/min

Exclusion Criteria:

  • Absolute neutrophil count less than 500 cells/μL
  • Pregnancy
  • End-stage heart failure (NYHA stage IV)
  • Pulmonary embolism with obstructive shock
  • Ongoing bleeding
  • Atonic coma
  • More than 30 points on the MELD scale, class C on the Child-Pugh scale
  • HIV infection
  • Burns over 10% of the body surface area
  • Patients with oncohematological diseases
  • Patients with a recognized palliative status or the definition of "metastatic cancer"
  • RRT using membranes with a high cutoff point and increased adsorption capacity within 72 hours from the initiation of the first hemoadsorption procedure
  • Use of plasma exchange within 72 hours from the initiation of the first hemoadsorption procedure

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Dubbel

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Inflammatory mediatiors adsorption with CytoSorb
Inflammatory mediatiors adsorption with EAA <0,6 with CytoSorb
Blood purification with Jafron HA 330
Aktiv komparator: Inflammatory mediatiors adsorption with Jafron HA 330
Inflammatory mediatiors adsorption with EAA <0,6 with Jafron HA 330
Blood purification with Jafron HA 330
Experimentell: Endotoxin haemoadsorption with Toramyxin PMX 20R
Endotoxin haemoadsorption with EAA [0.6-0.9] with Toramyxin PMX 20R
Blood purification with Toramyxin PMX 20R
Aktiv komparator: Endotoxin haemoadsorption with Efferon LPS
Endotoxin haemoadsorption with EAA [0.6-0.9] with Efferon LPS
Blood purification with Efferon LPS

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
SOFA (sequential organ failure assessment) score
Tidsram: Assessed at 72 hours after hemoadsorption initiation
MODS (multiple organ disfunction syndrome) dynamics majored by SOFA (sequential organ failure assessment) score. SOFA score ranges from 0 (best) to 24 (worst) points.
Assessed at 72 hours after hemoadsorption initiation

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Lactate level dynamics
Tidsram: Assessed at 4 time points: before hemoadsorption initiation (baseline); 24 hours, 48 hours and 72 hours after hemoadsorption initiation
Lactate level dynamics (mmol/l)
Assessed at 4 time points: before hemoadsorption initiation (baseline); 24 hours, 48 hours and 72 hours after hemoadsorption initiation
Total bilirubin level dynamics
Tidsram: Assessed at 4 time points: before hemoadsorption initiation (baseline); 24 hours, 48 hours and 72 hours after hemoadsorption initiation
Total bilirubin level dynamics (mcmol/l)
Assessed at 4 time points: before hemoadsorption initiation (baseline); 24 hours, 48 hours and 72 hours after hemoadsorption initiation
Indirect bilirubin level dynamics
Tidsram: Time Frame: Assessed at 4 time points: before hemoadsorption initiation (baseline); 24 hours, 48 hours and 72 hours after hemoadsorption initiation
Indirect bilirubin level dynamics (mcmol/l)
Time Frame: Assessed at 4 time points: before hemoadsorption initiation (baseline); 24 hours, 48 hours and 72 hours after hemoadsorption initiation
Direct bilirubin level dynamics
Tidsram: Time Frame: Assessed at 4 time points: before hemoadsorption initiation (baseline); 24 hours, 48 hours and 72 hours after hemoadsorption initiation
Direct bilirubin level dynamics (mcmol/l)
Time Frame: Assessed at 4 time points: before hemoadsorption initiation (baseline); 24 hours, 48 hours and 72 hours after hemoadsorption initiation
Ferritin level dynamics
Tidsram: Time Frame: Assessed at 4 time points: before hemoadsorption initiation (baseline); 24 hours, 48 hours and 72 hours after hemoadsorption initiation
Ferritin level dynamics (mcg/l)
Time Frame: Assessed at 4 time points: before hemoadsorption initiation (baseline); 24 hours, 48 hours and 72 hours after hemoadsorption initiation
28 - days mortality
Tidsram: Will be calculated for 28 days after hemoadsorption initiation
28 - days mortality
Will be calculated for 28 days after hemoadsorption initiation
90 - days mortality
Tidsram: Will be calculated for 90 days after hemoadsorption initiation
90 - days mortality
Will be calculated for 90 days after hemoadsorption initiation
Vasoactive Inotropic Score (VIS) dynamics
Tidsram: Assessed at 4 time points: before hemoadsorption initiation (baseline); 24 hours, 48 hours and 72 hours after hemoadsorption initiation

Vasoactive Inotropic Score (VIS) dynamics

VIS = dopamine dose (mcg∕kg∕ min ) + dobutamine dose (mcg∕kg∕ min ) + 100 × epinephrine dose (mcg∕kg∕ min ) + 10 × milrinone dose (mcg∕kg∕ min ) + 10,000 × vasopressin dose (units∕kg∕ min )

+ 100 × norepinephrine dose (mcg∕kg∕ min )

Assessed at 4 time points: before hemoadsorption initiation (baseline); 24 hours, 48 hours and 72 hours after hemoadsorption initiation
Norepinephrine dose dynamics
Tidsram: Assessed at 4 time points: before hemoadsorption initiation (baseline); 24 hours, 48 hours and 72 hours after hemoadsorption initiation
Norepinephrine dose dynamics (mcg/kg/min)
Assessed at 4 time points: before hemoadsorption initiation (baseline); 24 hours, 48 hours and 72 hours after hemoadsorption initiation
Hemodynamic index dynamics
Tidsram: Assessed at 4 time points: before hemoadsorption initiation (baseline); 24 hours, 48 hours and 72 hours after hemoadsorption initiation

Hemodynamic index: Mean arterial pressure (MAP) to Vasoactive Inotropic Score (VIS);

VIS = dopamine dose (mcg∕kg∕ min ) + dobutamine dose (mcg∕kg∕ min ) + 100 × epinephrine dose (mcg∕kg∕ min ) + 10 × milrinone dose (mcg∕kg∕ min ) + 10,000 × vasopressin dose (units∕kg∕ min ) + 100 × norepinephrine dose (mcg∕kg∕ min )

Assessed at 4 time points: before hemoadsorption initiation (baseline); 24 hours, 48 hours and 72 hours after hemoadsorption initiation
Horowitz index dynamics
Tidsram: Assessed at 4 time points: before hemoadsorption initiation (baseline); 24 hours, 48 hours and 72 hours after hemoadsorption initiation
Arterial oxygen partial pressure (PaO2)/fraction of inspired oxygen (FiO2) ratio (Horowitz index) dynamics
Assessed at 4 time points: before hemoadsorption initiation (baseline); 24 hours, 48 hours and 72 hours after hemoadsorption initiation
Procalcitonin (PCT) level dynamics
Tidsram: Time Frame: Assessed at 4 time points: before hemoadsorption initiation (baseline); 24 hours, 48 hours and 72 hours after hemoadsorption initiation
Procalcitonin (PCT) level dynamics (ng/ml)
Time Frame: Assessed at 4 time points: before hemoadsorption initiation (baseline); 24 hours, 48 hours and 72 hours after hemoadsorption initiation
C- reactive protein (CRP) level dynamics
Tidsram: Time Frame: Assessed at 4 time points: before hemoadsorption initiation (baseline); 24 hours, 48 hours and 72 hours after hemoadsorption initiation
C- reactive protein (CRP) level dynamics (mg/l)
Time Frame: Assessed at 4 time points: before hemoadsorption initiation (baseline); 24 hours, 48 hours and 72 hours after hemoadsorption initiation
NLR (neutrophil-to-lymphocyte ratio) dynamics
Tidsram: Time Frame: Assessed at 4 time points: before hemoadsorption initiation (baseline); 24 hours, 48 hours and 72 hours after hemoadsorption initiation
NLR (neutrophil-to-lymphocyte ratio) dynamics
Time Frame: Assessed at 4 time points: before hemoadsorption initiation (baseline); 24 hours, 48 hours and 72 hours after hemoadsorption initiation
PLR (Platelet-to-lymphocyte ratio) dynamics
Tidsram: Assessed at 4 time points: before hemoadsorption initiation (baseline); 24 hours, 48 hours and 72 hours after hemoadsorption initiation
PLR (Platelet-to-lymphocyte ratio) dynamics
Assessed at 4 time points: before hemoadsorption initiation (baseline); 24 hours, 48 hours and 72 hours after hemoadsorption initiation
TNF (Tumor necrosis factor-alpha) level dynamics
Tidsram: Assessed at 3 time points: before hemoadsorption initiation (baseline); 48 hours and 72 hours after hemoadsorption initiation
TNF (Tumor necrosis factor-alpha) level dynamics (pg/ml)
Assessed at 3 time points: before hemoadsorption initiation (baseline); 48 hours and 72 hours after hemoadsorption initiation
IL 6 (Interleukin 6) level dynamics
Tidsram: Assessed at 3 time points: before hemoadsorption initiation (baseline); 48 hours and 72 hours after hemoadsorption initiation
IL 6 (Interleukin 6) level dynamics (pg/ml)
Assessed at 3 time points: before hemoadsorption initiation (baseline); 48 hours and 72 hours after hemoadsorption initiation
IL 10 (Interleukin 10) level dynamics
Tidsram: Time Frame: Assessed at 3 time points: before hemoadsorption initiation (baseline); 48 hours and 72 hours after hemoadsorption initiation
IL 10 (Interleukin 10) level dynamics (pg/ml)
Time Frame: Assessed at 3 time points: before hemoadsorption initiation (baseline); 48 hours and 72 hours after hemoadsorption initiation
SOFA (sequential organ failure assessment) dynamics
Tidsram: Assessed at 4 time points: before hemoadsorption initiatioin (baseline); at 24, 48 and 120 hours after hemoadsorption initiation
MODS (multiple organ disfunction syndrome) dynamics majored by SOFA (sequential organ failure assessment) score
Assessed at 4 time points: before hemoadsorption initiatioin (baseline); at 24, 48 and 120 hours after hemoadsorption initiation
SOFA 2 (sequential organ failure assessment) dynamics
Tidsram: Assessed at 5 time points: before hemoadsorption initiatioin (baseline); at 24, 48, 72 and 120 hours after hemoadsorption initiation
MODS (multiple organ disfunction syndrome) dynamics majored by SOFA 2 (sequential organ failure assessment) score
Assessed at 5 time points: before hemoadsorption initiatioin (baseline); at 24, 48, 72 and 120 hours after hemoadsorption initiation

Andra resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Ventilator-free days
Tidsram: Will be calculated for 28 days after hemoadsorption initiation
Ventilator-free days
Will be calculated for 28 days after hemoadsorption initiation
Vasopressor-free days
Tidsram: Will be calculated for 28 days after hemoadsorption initiation
Vasopressor-free days
Will be calculated for 28 days after hemoadsorption initiation
Dialysis-free days
Tidsram: Will be calculated for 28 days after hemoadsorption initiation
Dialysis-free days
Will be calculated for 28 days after hemoadsorption initiation
Hospital length of stay
Tidsram: Will be calculated for 28 days after hemoadsorption initiation
Hospital length of stay
Will be calculated for 28 days after hemoadsorption initiation
Intensive care unit (ICU) length of stay
Tidsram: Will be calculated for 28 days after hemoadsorption initiation
Intensive care unit (ICU) length of stay
Will be calculated for 28 days after hemoadsorption initiation
AEs (adverse events)
Tidsram: Serious AEs will be reported up to Day 28
The safety will be assessed by analysing the number of adverse events (AEs) where causal relationship with the intervention cannot be excluded, up until Day 28.
Serious AEs will be reported up to Day 28

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Allmänna publikationer

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

25 juni 2026

Primärt slutförande (Beräknad)

25 juni 2027

Avslutad studie (Beräknad)

25 december 2027

Studieregistreringsdatum

Först inskickad

16 juni 2026

Först inskickad som uppfyllde QC-kriterierna

16 juni 2026

Första postat (Faktisk)

22 juni 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

2 juli 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

30 juni 2026

Senast verifierad

1 juni 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

IPD-planbeskrivning

De-identified individual participant data (IPD) that underlie the results reported in the primary publication (including baseline characteristics, blood purification parameters, hemodynamics and SOFA score dynamics, clinical outcomes) will be made publicly available to ensure absolute transparency and academic reproducibility.

Tidsram för IPD-delning

Data will become available immediately following the official publication of the primary trial results, approximately at 12/2027.

Kriterier för IPD Sharing Access

The dataset will be openly accessible to any researcher, clinician, or analyst interested in replicating the study findings, conducting systematic reviews, or performing secondary meta-analyses. The data will be hosted publicly, and no formal research proposal review or data use agreements are required for access.

IPD-delning som stöder informationstyp

  • STUDY_PROTOCOL
  • SAV
  • CSR

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera